## EU Pharma Firms Manipulate Trial Data for Faster Approval
Whispers from within regulatory bodies in Brussels suggest a systemic issue of data manipulation in clinical trials submitted by several mid-tier European pharmaceutical companies.  Sources indicate that minor adverse event data and statistically insignificant positive outcomes are being subtly altered or omitted to present a more favorable profile to the European Medicines Agency (EMA). This practice, while difficult to quantify precisely, is believed to be driven by intense market pressure and the desire for rapid market entry.  The implications are concerning, potentially leading to drugs with underestimated side effects or reduced efficacy reaching the market, impacting patient safety across the EU.  Internal audits have reportedly been lax, prioritizing speed over rigorous verification. This intelligence highlights a critical vulnerability in the EU's drug approval process.
---
- **Source**: 
- **Sector**: The Lab
- **Tags**: pharma fraud, ema, clinical trials, data manipulation, eu
- **Credibility**: unverified
- **Published**: 2026-02-28 13:27:30
- **ID**: 772
- **URL**: https://whisperx.ai/en/intel/772